Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | IL6ST | P40189 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9759140 | 0.86 | NAAA (0.43) | NAAABRD4PPARAIL6STFAAH | |
| SCHEMBL46356 | 0.85 | NAAA (0.48) | NAAABRD4PPARAIL6STIDH1 | |
| SCHEMBL2501460 | 0.85 | NAAA (0.48) | NAAABRD4PPARAIL6STIDH1 | |
| SCHEMBL2501454 | 0.85 | NAAA (0.48) | NAAABRD4PPARAIL6STIDH1 | |
| SCHEMBL5022262 | 0.84 | LTB4R (0.44) | NAAAIDH1CSNK2BCSNK2A1 | |
| SCHEMBL6422192 | 0.84 | HDAC1 (0.46) | NAAABRD4PPARAIL6STIDH1 | |
| SCHEMBL7346804 | 0.84 | HDAC1 (0.46) | NAAABRD4PPARAIL6STIDH1 | |
| SCHEMBL3372824 | 0.83 | NAAA (0.41) | NAAAPPARAFAAHCSNK2BCSNK2A1 | |
| SCHEMBL5564118 | 0.82 | HCRTR1 (0.42) | NAAAPPARAIL6STIDH1FAAH | |
| SCHEMBL5558781 | 0.81 | NAAA (0.44) | NAAAPPARAIL6STIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2014-07-31 | — | — | US | disclosed |
| US-8513429-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSITUTE FOR CANCER RESEARCH (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2012-12-13 | — | — | US | disclosed |
| US-8110590-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-02-07 | — | — | US | disclosed |
| US-7875638-B2 | desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; isomerization of the double bonds in the ring | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100197746-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2010-08-05 | — | — | US | disclosed |
| US-7759374-B2 | 12,13-desoxyepothilones, used as anticarcinogenic agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-20 | — | — | US | disclosed |
| US-7649006-B2 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090149516-A1 | Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof | DANISHEFSKY SAMUEL J | 2009-06-11 | — | — | US | disclosed |
| US-7384964-B2 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | DANISHEFSKY SAMUEL J | 2007-02-08 | — | — | US | disclosed |
| EP-1722791-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005084222-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050143429-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-06-30 | — | — | US | disclosed |
| US-20040053910-A1 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | CYP19A1 25/4885NAAA 4749/4885BRD4 2322/4885 |
| US-20100197746-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | CYP19A1 25/4885NAAA 4749/4885BRD4 2322/4885 |
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | CYP19A1 25/4885NAAA 4749/4885BRD4 2322/4885 |
| US-20090149516-A1 | Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof | DHPS, THPO, EPOR | CYP19A1 30/4885NAAA 4640/4885BRD4 2954/4885 |
| US-20040053910-A1 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | GSTA1, GSTO1, GGT1 | CYP19A1 50/4885NAAA 4489/4885BRD4 3854/4885 |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | CYP19A1 25/4885NAAA 4749/4885BRD4 2322/4885 |
| US-20050143429-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | DHPS, THPO, EPOR | CYP19A1 30/4885NAAA 4640/4885BRD4 2954/4885 |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | GSTA1, GSTO1, GSTA2 | CYP19A1 60/4885NAAA 3552/4885BRD4 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.